Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Pact Pharma Inc. is currently navigating 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution workload is distributed across 5 distinct examiners and 5 distinct art units. This distribution indicates a broad spread of intellectual property assets across different specialized groups within the USPTO.
The busiest examiner identified in the data is REDDIG, PETER J, who holds 1 pending office action. Since the busiest examiner pending count is 1, the portfolio does not show any clustering of cases under a single individual. Each of the 5 distinct examiners is handling a different matter, which may lead to varying prosecution timelines and examiner-specific requirements across the Biotechnology & Pharmaceuticals sector.
For a practitioner, this distribution across 5 distinct art units suggests that the company is pursuing diverse technical claims that fall under different examination guidelines. Managing the 5 pending office actions simultaneously requires coordination to ensure consistent terminology. The lack of concentration under any single examiner means that the outcome of a matter is less likely to directly influence the immediate procedural handling of others.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| CORDAS, EMILY ANN | 1 | 50.8% | +57.3% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| TIWARI, VYOMA SHUBHAM | 1 | 31.5% | +48.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18049114 | METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS | HOLLAND, PAUL J | — |
| 17487411 | PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES | TIWARI, VYOMA SHUBHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18332169 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY | REDDIG, PETER J | 97d overdue |
| 18306927 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY | LEE, YIE CHIA | 74d overdue |
| 18319743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY | CORDAS, EMILY ANN | — |
| 18049114 | METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS | HOLLAND, PAUL J | — |
| 17487411 | PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES | TIWARI, VYOMA SHUBHAM | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1632 | 1 |
| 1642 | 1 |
| 1656 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18332169 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T CELL IMMUNOTHERAPY | REDDIG, PETER J | 1646 | §102§103§112DP | Non-Final OA | 97d overdue | Pending | Jun 09, 2023 |
| 18319743 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY | CORDAS, EMILY ANN | 1632 | §103 | Non-Final OA | — | Pending | May 18, 2023 |
| 18306927 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY | LEE, YIE CHIA | 1642 | §103 | Final Rejection | 74d overdue | Pending | Apr 25, 2023 |
| 18049114 | METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS | HOLLAND, PAUL J | 1656 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2022 |
| 17487411 | PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES | TIWARI, VYOMA SHUBHAM | 1634 | §102§112 | Final Rejection | — | Pending | Sep 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial